Market revenue in 2023 | USD 1,529.6 million |
Market revenue in 2030 | USD 2,833.4 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Outsourcing |
Fastest growing segment | Outsourcing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | In-house, Outsourcing |
Key market players worldwide | Genpact Ltd, Criterium Inc., Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Holdings Inc, FREYR Battery Inc, Pharmexon, Cambridge Design Partnership, Voisin Consulting Life Sciences, Accell, PAREXEL, Promedica International, PharmaLex, NDA Regulatory Service GmbH, QVigilance, BlueReg Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs market will help companies and investors design strategic landscapes.
Outsourcing was the largest segment with a revenue share of 58.13% in 2023. Horizon Databook has segmented the China regulatory affairs market based on in-house, outsourcing covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the most attractive markets for the biopharmaceutical industry. Growing geriatric population and presence of a large pool of population belonging to the middle-income group are further increasing the demand for innovative and cost-effective medicines, which is expected to attract major biopharmaceutical and medical devices company in this region.
Seeking approval for new drugs is a primary challenge faced by biopharmaceutical companies as a clinical trial application process requires 12 to 24 months while approval process may require more than six years. Along with national approvals, the new drug requires approval at both provincial or city level, which may require additional four to five years.
Reforms in the healthcare sector in the recent times are expected to streamline the approval process. However, in the future, owing to increased government support to generics, innovative biopharmaceutical companies may be negatively impacted.
Horizon Databook provides a detailed overview of country-level data and insights on the China regulatory affairs market , including forecasts for subscribers. This country databook contains high-level insights into China regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account